ArticleJournal of infection and public health2026
High treatment success among individuals with rifampicin-resistant tuberculosis in Botswana: A retrospective cohort study.
Article in Journal of infection and public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
16 authors.
Funding
Abstract
backgroundRifampicin-resistant tuberculosis (RR-TB) remains a global health challenge, which is often characterized by limited treatment options and increased morbidity and mortality. Despite advances in diagnostics and the introduction of new drug regimens, treatment success for drug-resistant TB remains low. There is limited data on clinical, sociodemographic, and microbiological factors that influence patient outcomes. The aim of the study is to evaluate TB treatment outcomes among individuals diagnosed with RR-TB and to identify predictors of favourable and unfavourable treatment outcomes.
methodsWe conducted a retrospective study to analyse treatment outcomes of 162 individuals diagnosed with RR-TB using GeneXpert MTB/RIF and phenotypic drug susceptibility testing (pDST) from 2016 to 2023. Treatment outcome proportions were estimated using the binomial exact method with 95 % confidence intervals (CI). Predictors associated with unfavourable treatment outcomes were assessed using logistic regression models.
resultsOf the 162 individuals, 102(62.7 %) were male with a median age of 39 (interquartile range (IQR): 29-50). Most individuals, 78(48.1 %), were from the Greater Gaborone health district, and 88(54.3 %) were people living with HIV (PLWH). Among included individuals, 137(84.6 %, 95 % CI: 78.2-89.7) were successfully treated. Males had higher odds of unfavourable treatment outcomes compared to females (OR = 1.70; 95 % CI: 0.73-3.98). Among those cured, a slightly higher proportion was observed among PLWH (71.8 %, 95 % CI: 62.1-80.3) compared to people not living with HIV (PNLWH) (69.2 %, 95 % CI: 58.7-78.5). However, the mortality rate was higher among PLWH (10.7 %; 95 % CI: 5.5-18.3) than among PNLWH (6.6 %; 95 % CI: 2.5-13.8). Those with a history of TB treatment had 1.03 odds of unfavourable treatment outcomes (95 % CI: 0.40-2.73); however, this association was not statistically significant.
conclusionOur study shows a high rate of successful treatment outcomes among individuals with RR-TB, with no significant difference based on sex, TB treatment history, or HIV status. Higher mortality among PLWH highlights the need for targeted interventions among high-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.